Last reviewed · How we verify
MMV390048 formulation A
At a glance
| Generic name | MMV390048 formulation A |
|---|---|
| Sponsor | Medicines for Malaria Venture |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Viral Upper Respiratory Tract Infection
- Dyspepsia
- Nasal Congestion
- Constipation
- Upper Respiratory Tract Infection
- Injury
- Ligament Sprain
- Headache
- Rash
Key clinical trials
- A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers (PHASE1)
- Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMV390048 formulation A CI brief — competitive landscape report
- MMV390048 formulation A updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI